IMRX.US Immuneering Corp

Healthcare Biotechnology USA Stocks
3.71 USD
Close of Nov 15, 2026
3.35 8.48
Market cap
USD 240M
P/E
-
P/B
1.42x
ROE
-43.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is IMRX.US undervalued?

Graham number

The Graham number of Immuneering Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Immuneering Corp fundamental analysis

No fundamental analysis for Immuneering Corp yet.

Immuneering Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Immuneering Corp

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and mul…

Full company profile